Senior Machine Learning Scientist

About the role

Quotient Therapeutics is seeking a Machine Learning Scientist to build models and AI agents that translate somatic mutation data into evidence for drug target discovery. The role involves developing models of variant effects on protein function and creating agentic AI workflows to support hypothesis testing and decision-making. You will work on a cross-functional team to analyze complex biological data and contribute to the development of breakthrough medicines.

Responsibilities

• Build and evaluate models that predict how coding and non-coding variants affect protein function, stability, interactions and pathway activity, using protein language models, structure-based methods and related approaches.
• Use variant-effect predictions to interpret somatic selection signals, including whether mutations are likely loss-of-function, gain-of-function or neutral, and where they cluster in protein structure.
• Design, build and evaluate AI agents and agentic workflows that retrieve evidence, run analyses and support hypothesis testing and target assessment.
• Train, fine-tune or adapt foundation models, language models and representation-learning methods for target discovery.
• Use AI coding tools to speed up development while keeping code readable, tested and reproducible.
• Work as a core member of cross-functional project teams, share ownership of team goals, and contribute to shared codebases, reviews and tools.
• Communicate results clearly to scientists and target discovery leadership, including model assumptions, limitations and next steps.

Required skills

• Python
• Deep learning
• PyTorch
• JAX
• Machine learning
• Variant-effect prediction
• Protein language models
• AI agents

Qualifications

• PhD in machine learning, computer science, computational biology, genomics, bioinformatics, statistics, engineering or a related field
• MSc with equivalent experience

About the Company

Quotient Therapeutics is a privately-held, early stage company developing breakthrough medicines informed by natural somatic genetic diversity present in patients. The company was founded by Flagship Pioneering, an innovative enterprise that conceives, creates, resources, and grows first-in-category life sciences companies.